LONDON, June 18, 2015 /CNW/ -
-- Two oral presentations of GARFIELD-AF Registry data will provide
real-life insights into the impact of patient risk profiles and poor
anticoagulation control on stroke prevention in AF --
New analyses from the Global Anticoagulant Registry in the Field -
Atrial Fibrillation (GARFIELD-AF) will be presented at the XXV Congress
of the International Society on Thrombosis and Haemostasis (ISTH) in
Toronto, Canada, June 20-25, 2015. The two GARFIELD presentations will
include real-life data on stroke prevention from nearly 17,200
patients, providing physicians with further information on how patient
risk profiles and quality of vitamin K antagonist control are
associated with increased mortality and stroke in patients with newly
The GARFIELD-AF oral presentations at ISTH 2015 will cover:
Risk profiles and 1-year outcomes of patients with newly diagnosed
atrial fibrillation: Results from GARFIELD-AF (Abstract OR119)
• Oral Session: Oral Communications 2: Stroke
• Monday 22 June, 2015, 14:45-15:00, Room 709
The incidence of stroke/systemic embolism, death and major bleeding one
year after a new diagnosis of non-valvular AF were analysed by
patients' baseline characteristics and antithrombotic therapy provided
Quality of vitamin K antagonist control and 1-year outcomes: A global
perspective from the GARFIELD-AF Registry (Abstract OR096)
• Oral Session: Oral Communications 2: Vitamin K antagonists
• Monday 22 June, 2015, 14:00-14:15, Room 715
The study analysed time in therapeutic range (TTR) and optimal
international normalised ratio (i.e. INR range 2.0-3.0) in patients
with newly diagnosed non-valvular AF in relation to demographics, care
settings and 1-year outcomes.
The GARFIELD-AF Registry will enhance the breadth and depth of the
understanding of stroke prevention in AF, and ultimately will help to
develop strategies for improving patient outcomes worldwide.
Baseline data from GARFIELD-AF (now available for 31,666 patients)
indicates that, currently, the management of many newly diagnosed
patients is not consistent with evidence-based guidelines, with
patients inappropriately receiving anticoagulants or being
under-treated with anticoagulants, despite the increasing availability
of non-vitamin K antagonist oral anticoagulants (NOACs). The impact of
sub-optimal management strategies on outcomes demonstrated in the
GARFIELD-AF presentations at ISTH suggests a cause for ongoing concern.
GARFIELD-AF is an independent academic research initiative, led by an
international steering committee under the auspices of the Thrombosis
Research Institute (TRI), London, UK. To date, GARFIELD-AF has
recruited over 40,000 patients with newly diagnosed AF in 35 countries,
making it one of the largest observational studies in this therapeutic
area. With recruitment for Cohort 5 about to start, the Registry will
eventually include up to 57,000 patients.
About the GARFIELD-AF Registry
GARFIELD-AF is an observational, multicentre, international prospective
study of patients with newly diagnosed AF. It will prospectively
follow 57,000 patients from at least 1,000 centres in 35 countries in
the Americas, Eastern and Western Europe, Asia, Africa and Australia.
Contemporary understanding of AF is based on data gathered in controlled
clinical trials. Whilst essential for evaluating the efficacy and
safety of new treatments, these trials are not representative of
everyday clinical practice and, hence, uncertainty persists about the
real-life burden and management of this disease. GARFIELD-AF seeks to
provide insights into the impact of anticoagulant therapy on
thromboembolic and bleeding complications seen in this patient
population. It will provide a better understanding of the potential
opportunities for improving care and clinical outcomes amongst a
representative and diverse group of patients and across distinctive
populations. This should help physicians and healthcare systems to
appropriately adopt innovation to ensure the best outcomes for patients
The registry started in December 2009. Four key design features of the
GARFIELD-AF protocol ensure a comprehensive and representative
description of AF, these are:
• Five sequential cohorts of prospective, newly-diagnosed patients,
facilitating comparisons of discrete time periods and describing the
evolution of treatments and outcomes.
• Investigator sites that are selected randomly within carefully
assigned national AF care setting distributions, ensuring that the
enrolled patient population is representative.
• Enrolment of consecutive eligible patients regardless of therapy to
eliminate potential selection bias.
• Follow-up data captured for a minimum of 2 and up to 8 years after
diagnosis, to create a comprehensive database of treatment decisions
and outcomes in everyday clinical practice.
Included patients must have been diagnosed with non-valvular AF within
the previous 6 weeks and have at least one additional risk factor for
stroke; as such they are potential candidates for anticoagulant therapy
to prevent blood clots leading to stroke. It is left to the
investigator to identify a patient's stroke risk factor(s), which need
not be restricted to those included in established risk scores.
Patients are included whether or not they receive anticoagulant
therapy, so current and future treatment strategies and failures can be
properly understood in relation to patients' individual risk profiles.
The GARFIELD-AF Registry is funded by an unrestricted research grant
from Bayer Pharma AG.
The burden of AF
Up to 2% of the global population has AF. Around 6 million people in Europe, 3-5 million people in the United States, and up to 8 million people in China have AF., It is estimated that its prevalence will at least double by 2050 as the
global population ages. AF confers a five-fold increase in the risk of
stroke, and one in five of all strokes is attributed to this
arrhythmia. Ischaemic strokes associated with AF are often fatal, and
those patients who survive are left more frequently and more severely
disabled and more likely to suffer a recurrence than patients with
other causes of stroke. In consequence, the risk of death from
AF-related stroke is doubled and the cost of care is increased by 50%.
AF occurs when parts of the atria emit uncoordinated electrical signals.
This causes the chambers to pump too quickly and irregularly, not
allowing blood to be pumped out completely. As a result, blood may pool, clot and lead to thrombosis, which is the
number one cardiovascular killer in the world. If a blood clot leaves the left atrium, it could potentially lodge in
an artery in other parts of the body, including the brain. A blood clot
in an artery in the brain leads to a stroke. Ninety-two per cent of
fatal strokes are caused by thrombosis. People with AF also are at high risk for heart failure, chronic fatigue
and other heart rhythm problems. Stroke is a major cause of death and long-term disability worldwide -
each year 6.7 million people die and 5 million are left permanently disabled.
About the TRI
The TRI is a charitable foundation and multi-disciplinary research
institute dedicated to the study of thrombosis and related disorders.
TRI's mission is to provide excellence in thrombosis research and
education, to develop new strategies to prevent and treat thrombosis
and thereby improve quality of care, advance clinical outcomes and
reduce healthcare costs. The TRI is a member of University College
London Partners Academic Health Science System.
For more information, visit http://www.tri-london.ac.uk/garfield.
Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation
in the general population and in high-risk groups: the ECHOES study.
Europace 2012; 14(11):1553-9. 6/16/15. Available at: http://europace.oxfordjournals.org/content/14/11/1553.long
The Lancet Neurology. Stroke prevention: getting to the heart of the
matter. Lancet Neurol 2010; 9(2):129. 6/16/15. Available at: http://www.atrialfibrillation.org.uk/files/file/Articles_Medical/Lancet%20Neurology-%20getting%20to%20the%20heart%20of%20the%20matter.pdf
Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial
fibrillation and flutter in the United States. Am J Cardiol 2009;
Colilla S, Crow A, Petkun W, et al. Estimates of current and future
incidence and prevalence of atrial fibrillation in the U.S. adult
population. Am J Cardiol 2013; 112(8):1142-7. 6/16/15. Available at: http://www.ajconline.org/article/S0002-9149(13)01288-5/fulltext
Zhou Z, Hu D. An epidemiological study on the prevalence of atrial
fibrillation in the Chinese population of mainland China. J Epidermiol
2008; 18(5):209-16. 6/16/15. Available at: https://www.jstage.jst.go.jp/article/jea/18/5/18_JE2008021/_pdf
Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of
atrial fibrillation in China. JACC 2008; 52(10):865-8. 6/16/15.
Available at: http://www.sciencedirect.com/science/article/pii/S0735109708021141
European Heart Rhythm Association; European Association for
Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines
for the management of atrial fibrillation: the Task Force for the
Management of Atrial Fibrillation of the European Society of Cardiology
(ESC). 8/22/14. Eur Heart J 2010; 31(19):2369-429. 6/16/15. Available
National Heart, Lung, and Blood Institute. What is Atrial Fibrillation?
6/16/15. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/af/af_what.html
International Society on Thrombosis and Haemostasis. About World
Thrombosis Day. Available at: http://www.worldthrombosisday.org/about/
American Heart Association. Why Atrial Fibrillation (AF or AFib)
Matters. 8/22/14. Available at: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Why-Atrial-Fibrillation-AF-or-AFib-Matters_UCM_423776_Article.jsp
World Health Organization. The top 10 causes of death. Fact sheet No 310. Updated May 2014. 6/16/15. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/
World Heart Federation. The global burden of stroke. 6/16/15. Available
SOURCE Thrombosis Research Institute (TRI)